--- title: "Ocular Therapeutix (OCUL) news: lawsuit" url: "https://aibio.space/companies/ocular-therapeutix/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "OCUL lawsuit news: Ocular Therapeutix faces EyePoint defamation suit; injunction ruling still pending. Ocular Therapeutix, Inc." --- OCUL Ocular Therapeutix, Inc. NASDAQ · United States # Ocular Therapeutix (OCUL) news OCUL lawsuit news Legal · 2026-08-03 ## [Ocular Therapeutix faces EyePoint defamation suit; injunction ruling still pending](https://aibio.space/news/ocular-therapeutix-faces-eyepoint-defamation-suit-injunction-ruling/) EyePoint, Inc. sued Ocular in Massachusetts state court on March 20, 2026 over alleged false statements about DURAVYU. The court denied a restraining order on April 13 and has not ruled on a preliminary injunction. ## Latest Ocular Therapeutix news We have not published a story on Ocular Therapeutix yet. When there is news, it will appear here. ## Ocular Therapeutix at a glance - **Ticker**: OCUL - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $598.6 million ### Related companies - [Omeros](https://aibio.space/companies/omeros/) NASDAQ: OMER - [Oramed Pharmaceuticals](https://aibio.space/companies/oramed-pharmaceuticals/) NASDAQ: ORMP - [Agios Pharmaceuticals](https://aibio.space/companies/agios-pharmaceuticals/) NASDAQ: AGIO - [Merck & Company](https://aibio.space/companies/merck-mrk-nyse/) NYSE: MRK - [Nano Mobile Healthcare](https://aibio.space/companies/nano-mobile-healthcare/) OTC: VNTH - [OnKure Therapeutics](https://aibio.space/companies/onkure-therapeutics/) NASDAQ: OKUR - [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) NASDAQ: FULC - [Mangoceuticals](https://aibio.space/companies/mangoceuticals/) NASDAQ: MGRX ### Also on NASDAQ - [Tempus AI](https://aibio.space/companies/tempus-ai/) TEM - [Allarity Therapeutics](https://aibio.space/companies/allarity-therapeutics/) ALLR - [EyePoint](https://aibio.space/companies/eyepoint/) EYPT - [AURORA CANNABIS INC](https://aibio.space/companies/aurora-cannabis/) ACB - [Summit Therapeutics](https://aibio.space/companies/summit-therapeutics/) SMMT - [FEMASYS INC](https://aibio.space/companies/femasys/) FEMY ## What Ocular Therapeutix does Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on retinal disease and ophthalmic products. Its lead investigational product, AXPAXLI (OTX-TKI), is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel technology. AXPAXLI is in a Phase 3 registrational program for wet age-related macular degeneration, known as the SOL program, and in a Phase 3 registrational program for diabetic retinal disease, including non-proliferative diabetic retinopathy, known as the HELIOS program. The company's commercial product DEXTENZA, a drug-eluting intracanalicular insert, is approved by the FDA for ocular inflammation and pain following ophthalmic surgery and for ocular itching associated with allergic conjunctivitis. The ELUTYX technology is also used in OTX-TIC, a travoprost intracameral hydrogel that completed a Phase 2 trial for open-angle glaucoma or ocular hypertension. The company is evaluating next steps for OTX-TIC. The exudative retinal disease market that AXPAXLI targets accounted for approximately $9.4 billion in U.S. annual estimated revenues in 2025, according to a third-party report. AffaMed Therapeutics Limited holds a license and collaboration for DEXTENZA and OTX-TIC in certain Asian geographies. | Product or program | What it is | Stage | |---|---|---| | AXPAXLI (OTX-TKI) | Axitinib intravitreal hydrogel for wet AMD and diabetic retinal disease | Phase 3 | | DEXTENZA | Drug-eluting intracanalicular insert for ocular inflammation and pain | FDA approved | | OTX-TIC | Travoprost intracameral hydrogel for open-angle glaucoma or ocular hypertension | Phase 2 completed | Summarised from the company's [10-K filed Feb 5, 2026](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/ocul-20251231x10k.htm). ## Ocular Therapeutix annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$197.1 million](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/) | [$127.6 million](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/) | | Net income (loss) | [-$265.9 million](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/) | [-$193.5 million](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/) | | Cash from operations | [-$204.9 million](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/) | [-$134.7 million](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/) | | Cash and equivalents | [$737.1 million](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/) | [$392.1 million](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $598.6 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Ocular Therapeutix Is Ocular Therapeutix involved in a lawsuit? Our latest story on this, dated Aug 3, 2026: "Ocular Therapeutix faces EyePoint defamation suit; injunction ruling still pending". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/ocular-therapeutix-faces-eyepoint-defamation-suit-injunction-ruling/). What is the ticker symbol of Ocular Therapeutix? Ocular Therapeutix, Inc. trades under the ticker OCUL on NASDAQ. Where is Ocular Therapeutix listed? Ocular Therapeutix, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:0OT; LS:A1180P; LSX:A1180P. What is the SEC CIK of Ocular Therapeutix? The SEC Central Index Key (CIK) for Ocular Therapeutix, Inc. is 1393434. Its filings are on SEC EDGAR. How many shares does Ocular Therapeutix have outstanding? 219,615,868 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-03. Which country or territory is Ocular Therapeutix listed under? Our directory records Ocular Therapeutix, Inc. under United States. What does Ocular Therapeutix do? Our directory classifies Ocular Therapeutix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Ocular Therapeutix? The ISIN recorded for Ocular Therapeutix, Inc. is US67576A1007. Does aibio.space cover Ocular Therapeutix? aibio.space lists Ocular Therapeutix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Ocular Therapeutix incorporated? SEC records list its state or country of incorporation as DE. What does Ocular Therapeutix develop? Ocular Therapeutix, Inc. is an integrated biopharmaceutical company focused on retinal disease and ophthalmic products. Its lead investigational product, AXPAXLI (OTX-TKI), is an axitinib intravitreal hydrogel based on its ELUTYX bioresorbable hydrogel technology. What is AXPAXLI (OTX-TKI) from Ocular Therapeutix? AXPAXLI (OTX-TKI): Axitinib intravitreal hydrogel for wet AMD and diabetic retinal disease Stage: Phase 3. What is DEXTENZA from Ocular Therapeutix? DEXTENZA: Drug-eluting intracanalicular insert for ocular inflammation and pain Stage: FDA approved. Is Ocular Therapeutix profitable? Ocular Therapeutix, Inc. reported a net loss of $265.9 million for the fiscal year ended Dec 31, 2025, and used $204.9 million of cash in operations, per its annual report to the SEC. How much does Ocular Therapeutix spend on research and development? $197.1 million in the fiscal year ended Dec 31, 2025, per its annual report. ## Investor discussion: Ocular Therapeutix Members talk about Ocular Therapeutix (OCUL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Ocular Therapeutix, newest first. Each line links the filing it comes from. 1. 2026-02-05 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1393434/000110465926010664/ocul-20251231x10k.htm) 2. 2025-09-30 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1393434/000110465925094758/tm2527344d1_ex99-1.htm) 3. 2025-03-03 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1393434/000155837025002000/ocul-20241231x10k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:OCUL on TradingView](https://www.tradingview.com/symbols/NASDAQ-OCUL/). ## SEC filings and registration - **SEC name**: Ocular Therapeutix, Inc - **CIK**: 1393434 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: OCUL (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 14 CROSBY DRIVE, 3RD FLOOR, BEDFORD, MA, 01730 - **Phone**: 781-357-4000 - **Shares outstanding**: 219,615,868 as of 2026-07-31 (10-Q filed 2026-08-03) - **Former names**: I-THERAPEUTIX INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1393434/000110465926116617/tm2627709d1_8k.htm) filed 2026-10-16 - [10-Q](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_8k.htm) filed 2026-08-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1393434/000110465926073496/tm2617802d1_8k.htm) filed 2026-06-12 - [10-Q](https://www.sec.gov/Archives/edgar/data/1393434/000110465926055256/ocul-20260331x10q.htm) filed 2026-05-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_8k.htm) filed 2026-05-05 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1393434/000110465926053176/ocul-20260611xdef14a.htm) filed 2026-04-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1393434/000110465926021541/tm267471d2_8k.htm) filed 2026-02-27 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001393434), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Ocular Therapeutix, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker OCUL, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Ocular Therapeutix, Inc. - **Ticker**: OCUL - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US67576A1007 - **Other listed symbols**: GETTEX:0OT; LS:A1180P; LSX:A1180P - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-OCUL/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/ocular-therapeutix/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Ocular Therapeutix (OCUL) news: lawsuit", 2026-10-31, https://aibio.space/companies/ocular-therapeutix/